Abstract 273P
Background
EBC care is multidisciplinary and should include comprehensive and timely management of tx-related SE. We assessed patient-reported experiences and preferences about information on SE received during EBC care.
Methods
An international multi-stakeholder expert group (oncology, surgery, nursing, pharmacy, psychology, patient advocacy, industry) was formed and conducted a patient survey (by email and phone follow-up) assessing comprehensiveness, timing, and delivery modality of information about tx-related SE. Patients with EBC that were on primary (PTx) or endocrine therapy (ET) or had discussed tx options with a health care provider (HCP) were eligible. Descriptive analyses were performed.
Results
From June-August 2023, 608 respondents from Brazil (n=101), France (n=100), Germany (n=100), Italy (n=106), Japan (n=101), and Spain (n=100) completed the survey: 58% were <50 years old, 92% were female, 14% had been diagnosed with EBC ≥10 years earlier, and all were or had been on ET. Fatigue was the most common SE during PTx and ET (47% and 42%, respectively), with 47% and 51% of pts reporting very high impact on quality of life (QOL). Among pts on PTx and ET, respectively, 69% and 71% reported receiving sufficient or very comprehensive information on fatigue and its management, 63% and 65% reported receiving the information before the onset of fatigue symptoms. Fewer patients reported urinary problems during PTx and ET (8% and 5%), however 67% and 61%, respectively, reported a very high impact of symptoms on QOL. Most patients would prefer the HCP to be proactive in providing information on SE (74%), preventative strategies (73%), and self-management programs (71%). Information received during direct interactions with a physician (70%) or nurse (58%) was deemed likely to improve management of SE (vs printed materials, websites, or support groups).
Conclusions
This expert group recommends leveraging pts’ direct feedback to deliver personalized, detailed, and actionable information on SE and their management, including for the least prevalent ones. Co-creation of tailored communication strategies can enhance pts’ empowerment and engagement, improve the quality of EBC care, and limit tx impact on QOL.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
A. Di Meglio: Financial Interests, Personal, Expert Testimony: Techspert, Kephren. M. Coersmeyer, S. Ujupan: Financial Interests, Personal, Full or part-time Employment: Eli Lilly. All other authors have declared no conflicts of interest.